N,1-dimethylcyclopropane-1-carboxamide | 950605-12-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,1-dimethylcyclopropane-1-carboxamide
• 英文别名: N,1-dimethyl-cyclopropanecarboxamide
• CAS: 950605-12-6
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: DOAPHUAVDBBCPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
  申请人：GRUNENTHAL GMBH

  公开号：US20140066426A1

  公开（公告）日：2014-03-06

  The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及带有氟甲基基团的吡咯酮羧酰胺作为电压门控钙通道阻滞剂，以及含有这些化合物的药物组合物，还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• [EN] BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES<br/>[FR] BENZIMIDAZOLES POUR UNE UTILISATION DANS LE TRAITEMENT DU CANCER ET DES MALADIES INFLAMMATOIRES
  申请人：CAPELLA THERAPEUTICS INC

  公开号：WO2017053537A1

  公开（公告）日：2017-03-30

  Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.

  本文提供了使用苯并咪唑类化合物治疗、预防或改善由脂质激酶或蛋白激酶介导的疾病、紊乱或症状的方法，例如公式I或II的苯并咪唑类化合物及其药物组合物。本文还提供了苯并咪唑类化合物及其药物组合物，以及它们用于治疗、预防或改善增生性疾病症状的方法。
• COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDFGR
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US20170022206A1

  公开（公告）日：2017-01-26

  Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.

  这里描述了用于治疗与KIT和PDGFR相关疾病的化合物和组合物。
• PHENYL DERIVATIVES AND THEIR USE AS A MEDICAMENT
  申请人：Poitout Lydie

  公开号：US20100056507A1

  公开（公告）日：2010-03-04

  The present invention relates to new phenylic derivatives exhibiting a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. These derivatives are of particular interest in a method for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said new phenylic derivatives and to methods for the preparation and use thereof.

  本发明涉及新的苯基衍生物，具有良好的亲和力，特别是对CB2受体的某些亚型。这些衍生物在治疗涉及一个或多个大麻素受体的病理条件和疾病的方法中具有特殊的兴趣。本发明还涉及含有这些新的苯基衍生物的药物组合物，以及其制备和使用方法。
• AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2832731A1

  公开（公告）日：2015-02-04

  The present invention is related to a compound represented by formula (I) wherein R1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is -N(R3)-, -O-, or -S-; Y is =C(R4)-, or =N-; Z is -N(R7)-, -O-, or -S-; R2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: -(CR2aR2b)n-R2c, wherein R2a is each independently a hydrogen atom, halogen, or the like; R2b is each independently a hydrogen atom, halogen, or the like; R2a and R2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R2a which are attached to the adjacent carbon atoms and/or two of R2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R3 and R7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R4 and R5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物 其中 R1 是氢原子、取代或未取代的烷基、取代或未取代的芳香族羰基或类似物；X 是-N(R3)-、-O-或-S-；Y 是＝C(R4)-、或＝N-；Z 是-N(R7)-、-O-或-S-； R2 是取代或未取代的烷氧基，或类似物，或下式所代表的基团：-(CR2aR2b)n-R2c，其中 R2a 各自独立地为氢原子、卤素或类似物；R2b 各自独立地为氢原子、卤素或类似物；连接到相同碳原子上的 R2a 和 R2b 可一起形成氧代、取代或未取代的非芳香族碳环或类似物；与相邻碳原子相连的两个 R2a 和/或与相邻碳原子相连的两个 R2b 可结合在一起形成键； R2c 是取代或未取代的芳香族碳环或类似物； n 是 1 到 3 的整数； R3 和 R7 各自独立地为氢原子、取代或未取代的烷基或类似物； R4 和 R5 各自独立地为氢原子、卤素、取代或未取代的烷基或类似物； R6 是氢原子、卤素、取代或未取代的烷基或类似物、 或其药学上可接受的盐，或由其组成的药物组合物。